US 12,480,949 B2
Methods for treating non-small lung cancer and for preparing a sample
Sang Jun Ha, Seoul (KR); Hye Ryun Kim, Seoul (KR); Hyo Sup Shim, Seoul (KR); Bo Ryeong Lee, Seoul (KR); Jung Yeon Yi, Sejong (KR); and Dae Hee Hwang, Daegu (KR)
Assigned to INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY, Seodaemun-gu (KR); and REPUBLIC OF KOREA (MINISTER OF FOOD AND DRUG SAFETY), Chungcheongbuk-do (KR)
Appl. No. 17/271,441
Filed by INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY, Seoul (KR); and REPUBLIC OF KOREA (MINISTER OF FOOD AND DRUG SAFETY), Chungcheongbuk-do (KR)
PCT Filed Aug. 28, 2019, PCT No. PCT/KR2019/011022
§ 371(c)(1), (2) Date Feb. 25, 2021,
PCT Pub. No. WO2020/045996, PCT Pub. Date Mar. 5, 2020.
Claims priority of application No. 10-2018-0102288 (KR), filed on Aug. 29, 2018.
Prior Publication US 2021/0325394 A1, Oct. 21, 2021
Int. Cl. G01N 33/574 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01)
CPC G01N 33/57423 (2013.01) [A61P 35/00 (2018.01); C07K 14/70532 (2013.01); C07K 14/70596 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); G01N 2333/70503 (2013.01); G01N 2333/70532 (2013.01); G01N 2333/70596 (2013.01)] 8 Claims
 
1. A method of treating non-small lung cancer in a patient having received a first cancer immunotherapy treatment, comprising:
measuring expression levels of PD-L1 and poliovirus receptor (PVR), respectively, in a biological sample isolated from the patient;
evaluating a therapeutic response to the cancer immunotherapy for the subject, based on the measured expression levels of PD-L1 and PVR;
administering a second cancer immunotherapy treatment of one of an anti-PD-1 therapy, an anti-TIGIT therapy, and combined anti-PD-1/anti-TIGIT therapy based on the results of the evaluation,
wherein the biological sample includes at least one selected from a group consisting of tumor tissue, blood, serum, and plasma.